Treatment

Treatment options are available to people in recovery. Learn about resources available to people with use disorders and their friends and families.

Find Treatment

Overdose Response

Opioids cause death by slowing, and eventually stopping, a person's breathing. However, quick response can prevent brain injury and death.

FDA’s Naloxone App Prize Competition Celebrates Innovation In Search of Technological Solutions to the Opioid Epidemic
FDA launched this competition to develop innovative solutions to the problem of how to rapidly connect naloxone carriers to a person experiencing an opioid overdose.

FDA Supports Greater Access to Naloxone to Help Reduce Opioid Overdose Deaths
FDA is taking actions to help manufacturers pursue approval of an over-the-counter (OTC) naloxone product.

Naloxone Webpage
The National Institute on Drug Abuse (NIDA) created an online resource to raise awareness about naloxone.

Opioid Overdose Prevention Toolkit - Updated 2016
This toolkit from the Substance Abuse and Mental Health Services Administration (SAMHSA) equips communities and local governments with material to develop policies and practices to help prevent opioid-related overdoses and deaths.

Naloxone Toolkit
This toolkit from the Bureau of Justice Assistance provides basic information, resources, and guidance on using naloxone to treat overdose.

Opioid Auto-Injector Can Help Prevent Overdose Deaths
Read the Food and Drug Administration (FDA) blog post from April 3, 2014, when the auto-injector was approved for overdose treatment.

FDA moves quickly to approve easy-to-use nasal spray to treat opioid overdose
Read this press release from November 18, 2015 about how naloxone in nasal spray form provides an important new alternative for family members and first responders.

New effort targets drug overdoses in Indian Country
On December 16, 2015, the Bureau of Indian Affairs (BIA), White House Office of National Drug Control Policy (ONDCP), and Indian Health Service (IHS) announced the provision of naloxone to help reduce the rate of opioid overdoses in American Indian and Alaska Native communities.

IHS Increases Access to Naloxone to Save Lives in Indian Country
Read this blog post from Dr. Susan V. Karol, Chief Medical Officer at the Indian Health Service (IHS), on how the IHS worked with the BIA and ONDCP to increase access to naloxone in tribal communities.

Naloxone Training Video from the Baltimore City Health Department
In the video, Baltimore City Health Commissioner Dr. Leana Wen talks about the dangers of opioid misuse, symptoms to recognize an opioid overdose, and demonstrates a 5-step process, including how to assemble a naloxone kit and how to administer naloxone intranasally. Additional information is available on the website http://dontdie.org/.

Medication-Assisted Treatment

Medication-assisted treatment (MAT), including opioid treatment programs (OTPs), combines behavioral therapy and medications to treat substance use disorders. These medications relieve withdrawal symptoms and psychological cravings that cause chemical imbalances in the body.

Medications Used in MAT
The Food and Drug Administration (FDA) has approved three medications to treat opioid use disorder. Learn about these treatments and where to find more information.

Methadone
Methadone is used in MAT to help people reduce or quit their use of opioids. Find out how methadone works, what its side effects are, how it treats opioid use disorder, and where to find training and additional resources.

Methadone Treatment for Pregnant Women
This brochure urges pregnant women who use heroin or abuse opioid prescription drugs to seek methadone maintenance treatment. Learn how methadone therapy works, and read about related issues such as breastfeeding, infant withdrawal, birth control, and child protection services.

Buprenorphine
Buprenorphine is used in MAT to help people reduce or quit their use of opioids. Find out how buprenorphine works, what its side effects are, how it treats opioid use disorder, and where to find training and additional resources.

The Facts about Buprenorphine for Treatment of Opioid Addiction
This brochure from SAMHSA gives patients information on buprenorphine and medication-assisted treatment for opioid use idisorder.

An Introduction to Extended-Release Injectable Naltrexone for the Treatment of People with Opioid Dependence
The extended-release injectable naltrexone (Vivitrol) is a treatment option for opioid dependence. This report from SAMHSA discusses how naltrexone differs from other medication-assisted treatments, safety concerns, and patients most likely to benefit from this treatment.

Drug Courts

Drug Courts
Drug courts are specialized court docket programs that target criminal defendants and offenders, juvenile offenders, and parents with pending child welfare cases who have alcohol and other drug dependency problems.

Adult Drug Courts and Medication-Assisted Treatment for Opioid Dependence
Drug courts help participants recover from use disorder and prevent future criminal activity while also reducing the burden and costs of repeatedly processing low‐level, non‐violent offenders through the nation's courts, jails, and prisons. SAMHSA presents the use of MAT for opioid dependence in drug courts. This report reviews effective medications and provides strategies to increase the use of MAT in drug court programs.

Resources for Clinicians

Medication-Assisted Treatment (MAT)
SAMHSA presents forms, training materials, OTP data, and other resources on MAT.

An Introduction to Extended-Release Injectable Naltrexone for the Treatment of People with Opioid Dependence
The extended-release injectable naltrexone (Vivitrol) is a treatment option for opioid dependence. This report from SAMHSA discusses how naltrexone differs from other medication-assisted treatments, safety concerns, and patients most likely to benefit from this treatment.

Apply for Opioid Treatment Program (OTP) Certification
Learn the process for having your OTP certified by SAMHSA and access relevant resources.

Medication-Assisted Treatment of Opioid Use Disorder: Pocket Guide
This pocket guide from SAMHSA provides a checklist for prescribing medication, FDA-approved medications for use in the treatment of opioid use disorder, screening and assessment tools, and best practices for patient care.

Treating Opioid Abuse

Medications to Treat Opioid Addiction

Opioid Overdose Reversal with Naloxone (Narcan, Evzio)

Risk Evaluation and Mitigation Strategy (REMS) for Extended-Release and Long-Acting Opioid Analgesics
An important component of the ER/LA Opioid Analgesics REMS program is essential safety education for prescribers of these medications, along with information that prescribers can use when counseling patients.

Federal Guidelines for Opioid Treatment Programs
SAMHSA presents updated guidelines for the operation of opioid treatment programs (OTPs). This guidance covers patient assessment, treatment planning, medication-assisted treatment (methadone and buprenorphine), overdose and relapse prevention, and recovery care.

SAMHSA Releases Revised Guidelines for Opioid Treatment Program
SAMHSA published guidelines to help prescribers interpret the laws for how medications such as methadone and buprenorphine can be used. Read more about the guidelines and how they are organized.

A Collaborative Approach to the Treatment of Pregnant Women with Opioid Use Disorders
This SAMHSA guidance publication is intended to support the efforts of states, tribes, and local communities in addressing the needs of pregnant women with opioid use disorders and their infants and families.

Advancing the Care of Pregnant and Parenting Women with OUD and Their Infants
SAMHSA, with oversight by a steering committee of 13 other federal agencies and offices, has undertaken to develop a clinical guide that will inform health providers’ decisions regarding the evaluation, care, and treatment of pregnant and parenting women with opioid use disorder and their opioid-exposed infants.

Medication-Assisted Treatment Prescribing

Sublingual and Transmucosal Buprenorphine for Opioid Use Disorder: Review and Update
This update reviews current information on the use of sublingual and transmucosal buprenorphine for the medication-assisted treatment of opioid use disorder.

FDA Approves first buprenorphine implant for treatment of opioid dependence
FDA news release from May 26, 2016 announcing the approval of Probuphine, and how expanded use and availability of medication-assisted treatment is a top priority in addressing the opioid epidemic.

Narcotic Treatment Programs Best Practice Guideline
The Drug Enforcement Administration (DEA) presents a guideline on best practices for each aspect of narcotic treatment programs. Topics include ordering medication, dispensing medication, recordkeeping, and security measures.

Clinical Use of Extended-Release Injectable Naltrexone in the Treatment of Opioid Use Disorder: A Brief Guide
SAMHSA offers guidance on the use of medication-assisted treatment (MAT) with extended-release injectable naltrexone for the treatment of an opioid use disorder. This guidance covers assessing patients, initiating MAT, monitoring progress, and deciding when to end treatment.

Medication-Assisted Treatment for Opioid Addiction in Opioid Treatment Programs: Inservice Training Based on TIP 43
SAMHSA provides a training program for substance abuse treatment counselors and other clinicians on medication-assisted treatment for opioid use disorder. Training covers basic principles, best practices, history, and regulation. Includes scripted modules and handouts.

Medication-Assisted Treatment for Opioid Addiction in Opioid Treatment Programs: KAP Keys for Clinicians Based on TIP 43
Based on treatment improvement protocol 43, SAMHSA offers clinicians information on medications for opioid use disorder treatment, including side effects, drug interactions, and take-home doses. This guidance discusses patient counseling, associated medical problems, hepatitis C evaluation, drug testing, and pregnant women.

Medication-Assisted Treatment for Opioid Addiction in Opioid Treatment Programs: Quick Guide for Clinicians Based on TIP 43
SAMHSA presents a quick guide for clinicians on using medication-assisted treatment in opioid treatment programs. This guide discusses screening, pharmacology of five medications, pharmacotherapy, phases of treatment, drug testing, patients with special needs, and administrative issues.

Pharmacologic Guidelines for Treating Individuals with Post-Traumatic Stress Disorder and Co-Occurring Opioid Use Disorders
SAMHSA offers guidelines for medication-assisted treatment for individuals, particularly veterans, with post-traumatic stress disorder (PTSD) and co-occurring opioid use disorders.

Webinar in Innovative Practices in MAT and Primary Care
This Office of National Drug Control Policy (ONDCP) webinar showcases two MAT approaches which integrate care for individuals with substance use disorders and regular medical care.

Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction
Practice guidelines help physicians make decisions about using buprenorphine to treat opioid addiction. This publication includes information on patient assessment, and protocols for opioid withdrawal and the treatment of pregnant women, teens, and polysubstance users.

MATx Mobile App to Support Medication-Assisted Treatment of Opioid Use Disorder
This SAMHSA app supports practitioners who currently provide medication-assisted treatment (MAT), as well as those who plan to do so in the future.